Bioavailability of Subcutaneous vs Intramuscular Makena in Healthy Post-menopausal Women

Phase 1, randomised, open-label trial of hydroxyprogesterone caproate in preterm birth (2 arms), sponsored by AMAG Pharmaceuticals, Inc. Primary endpoints: Area Under the Curve to the Last Time With a Concentration ≥ LLOQ at 9 weeks, Area Under the Curve to Infinity at 9 weeks and 1 more. Started Sep 2016; status: completed.